Printer Friendly

POTENTIAL NEW CANCER THERAPEUTIC DEVELOPED BY IMMUNOMEDICS AND NATIONAL CANCER INSTITUTE TEAM; RESULTS PRESENTED AT CANCER MEETING

 POTENTIAL NEW CANCER THERAPEUTIC DEVELOPED BY IMMUNOMEDICS AND NATIONAL CANCER INSTITUTE TEAM; RESULTS PRESENTED AT CANCER MEETING
 WARREN, N.J., May 21 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) announced that scientists of the National Cancer Institute presented today at the annual meeting of the American Association for Cancer Research, in San Diego, promising results of a new cancer therapeutic consisting of a bacterial toxin (Pseudomonas exotoxin) attached to Immunomedics' anti-cancer targeting antibody (LL2). The antibody toxin conjugate induced the regression of lymphomas in animal testing.
 "This preclinical testing involved a derivative of Pseudomonas exotoxin modified by gene cloning to eliminate the normal cell binding property, which causes death of non-cancer cells. By attaching the Pseudomonas exotoxin directly to an antibody that is specific to lymphomas, cancer cells growing in mice were selectively destroyed by the toxin with minimal damage to normal cells," stated Ira Pastan, chief of Molecular Biology of the National Cancer Institute and co- investigator on this collaborative research project.
 In addition to testing Pseudomonas exotoxin as a cancer therapeutic, Immunomedics has two other new methods of cancer treatment in preclinical testing. One method involves the use of a tumor-targeting antibody directly labeled with the radioisotope rhenium-188, and the other method incorporates large amounts of doxorubicin, a commonly used cancer drug, labeled to an antibody specific to colorectal cancer.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
 -0- 5/21/92
 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


SH-OS -- NY023 -- 2695 05/21/92 10:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 21, 1992
Words:304
Previous Article:SECOND QUARTER EARNINGS SOAR AT J & J SNACK FOODS
Next Article:NOCOPI ANNOUNCES EUROPEAN AGREEMENT
Topics:


Related Articles
IMMUNOMEDICS ALLOWED PATENT FOR NEW CANCER IMAGING & THERAPY METHODS & AGENTS: FEDERAL GRANT FOR CANCER THERAPEUTIC ALSO AWARDED
IMMUNOMEDICS REPORT NEW RESULTS OF LUNG CANCER AND LYMPHOMA IMAGING AGENTS
IMMUNOMEDICS REPORTS RESULTS OF NEW CANCER THERAPEUTIC
IMMUNOMEDICS PRESENTS CANCER THERAPEUTICS AT THE AMERICAN COLLEGE OF NUCLEAR PHYSICIANS IN SAN DIEGO
IMMUNOMEDICS TO RESEARCH CANCER VACCINE UNDER FEDERAL GRANT
IMMUNOMEDICS' RADIOLABELED ANTIBODY SHOWS ACTIVITY IN OVARIAN CANCER
IMMUNOMEDICS REPORTS PROGRESS WITH CANCER THERAPEUTIC PROGRAM; EIGHT ABSTRACTS PRESENTED AT THE SOCIETY OF NUCLEAR MEDICINE CONFERENCE
Immunomedics and Beckman Coulter Form Joint Venture to Develop Cancer Therapeutics
Immunomedics Invents New Vaccine Technology For Cancer And Infectious Diseases.
Immunomedics Expands Cancer Therapy Focus in Research Agreement With National Cancer Institute.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters